-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines the PBS subsidised blinatumomab, dasatinib,
imatinib, inotuzumab and ponatinib for patients with acute lymphoblastic
leukaemia (ALL).

Acute lymphoblastic leukaemia and listing dates

Acute lymphoblastic leukaemia (ALL) is a type of blood cancer.

Listing dates:

-   dasatinib - 1 December 2007
-   imatinib - 1 December 2007
-   ponatinib – 1 November 2015
-   blinatumomab - 1 May 2017
-   inotuzumab ozogamicin - 1 May 2019

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to restriction and item codes, contact
details, application forms and the PBS and Services Australia websites.

Related links

Written Authority Required Drugs

Processing Complex Authority Required Listings

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

                                   

-   Services Australia ABN 90 794 605 008 
